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The presence of FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) is one of
the most frequent mutations in acute myeloid leukemia (AML) and is associated with an
unfavorable prognosis. FLT3 inhibitors, such as midostaurin, are used clinically but fail to
entirely eradicate FLT3-ITD+AML. This study introduces a new perspective and highlights
the impact of RAC1-dependent actin cytoskeleton remodeling on resistance to midostaurin in
AML. RAC1 hyperactivation leads resistance via hyperphosphorylation of the positive reg-
ulator of actin polymerization N-WASP and antiapoptotic BCL-2. RAC1/N-WASP, through
ARP2/3 complex activation, increases the number of actin filaments, cell stiffness and
adhesion forces to mesenchymal stromal cells (MSCs) being identified as a biomarker of
resistance. Midostaurin resistance can be overcome by a combination of midostaruin, the
BCL-2 inhibitor venetoclax and the RAC1 inhibitor Eht1864 in midostaurin-resistant AML cell
lines and primary samples, providing the first evidence of a potential new treatment approach
to eradicate FLT3-ITD+AML.
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Acute myeloid leukemia (AML) is a genetically hetero-geneous disease characterized by the clonal expansion ofimmature myeloid progenitor cells in the bone marrow
(BM). Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene
occur in ~30% of AML cases, with internal tandem duplications
(ITDs) being the most common type of mutation. These muta-
tions lead to constitutive autophosphorylation of the FLT3
receptor; consequently, growth factor signaling pathways are
activated. Thus, therapies that inhibit FLT3 kinase activity are
highly warranted to disrupt disease progression. Drug discovery
efforts have resulted in first- and second-generation FLT3 inhi-
bitors, which can be classified as type I and type II based on their
mechanism of interaction with the FLT3 receptor1. Type I inhi-
bitors, including sunitinib (first-generation), midostaurin (first-
generation), lestaurtinib (first-generation), crenolanib (second-
generation), and gilteritinib (second-generation) interact with the
ATP-binding site when the receptor is in the active conformation,
while type II inhibitors, such as sorafenib (first-generation),
ponatinib (first-generation), and quizartinib (second-generation),
interact with a hydrophobic region directly adjacent to the ATP-
binding domain that is accessible only when the receptor is
inactive and prevent receptor activation. Unlike type II inhibitors,
type I inhibitors reduce FLT3 phosphorylation in FLT3-ITD- and
FLT3-TKD-mutated AML cells, while type II inhibitors can target
FLT3-ITD but lack efficacy against TKD mutations, which exhibit
secondary mechanism resistance to type II inhibitors1–3. Gilter-
itinib and midostaurin have been approved by the US Federal
Drug Administration (FDA) to treat individuals with FLT3-
mutant AML. Nevertheless, FLT3-ITD AML is associated with
unfavorable prognosis, and patients develop drug resistance, with
the underlying mechanisms remaining largely unexplained4,5.
FLT3 receptor glycosylation and its autophosphorylation have
been associated with resistance to FLT3 inhibitors in FLT3-ITD
AML6–9. The exogenous expression of FLT3-ITD or FLT3-ITD
mutations leads to Ras-related C3 botulinum toxin substrate 1
(RAC1) activation10. RAC1 belongs to the RHO GTPase family
and is involved in many cellular functions, such as actin poly-
merization, cytoskeletal organization, migration, and apoptosis11.
The polymerization of actin monomers (known as G-actin) is
mainly carried out in four steps: (1) RAC1-GTP and phosphati-
dylinositol 4,5-bisphosphate (regulated positively by RAC1) bind
to WAVE2 and N-WASP; (2) WAVE2 and N-WASP undergo
conformational changes to an activated state; (3) the activated
forms of N-WASP and WAVE2 recruit the ARP2/3 complex; and
(4) the multiprotein complex comprising RAC1+ P-WAVE2 or
P-N-WASP+ARP2/3 initializes actin polymerization to form
actin filaments (known as F-actin)11–13. Moreover, profilin-1
(PFN1), which binds to N-WASP or WAVE proteins, can
accelerate actin polymerization14. Deregulation of this process
through increasing the number of actin filaments and cell stiffness
enhances the invasiveness and therapy resistance in solid
tumor15,16. Moreover, RAC1 inhibits apoptosis by binding to and
stabilizing antiapoptotic BCL-2 family proteins (BCL-2 and
MCL1) in colon cancer, cervical cancer, and B-cell
lymphoma17–19.
We hypothesized that FLT3 receptor phosphorylation and
glycosylation, which have been associated with FLT3 inhibitor
resistance, may induce RAC1 hyperactivation, which conse-
quently deregulates of actin dynamics and the antiapoptotic BCL-
2 family and may confer midostaurin resistance in FLT3-
mutant AML.
Results
FLT3-dependent RAC1 hyperactivation in FLT3-ITD+mid-
ostaurin-resistant cells. To study the role of RAC1-regulated
cellular processes in response to FLT3 inhibitors, we developed
midostaurin-resistant AML cell lines from the FLT3-ITD
homozygous and heterozygous AML cell lines MV4-11 and
MOLM-13, respectively. Parental cells are designated MID-Sens,
and midostaurin-resistant cells are designated MID-Res. The
IC50 of midostaurin in MV4-11 cells increased from 15.09 to
55.24 nM in MID-Sens and MID-Res cells; that of MOLM-13
cells increased from 29.41 to 87.83 nM (Fig. 1a). Afterwards, we
characterized FLT3 receptor glycosylation and phosphorylation
by western blotting, flow cytometry and direct stochastic optical
reconstruction microscopy (dSTORM). In MV4-11 and MOLM-
13 MID-Res cells, FLT3 receptor phosphorylation at tyrosine 969
(residue) was upregulated compared to that in their respective
MID-Sens cell lines (Figs. 1b and S5). Additionally, FLT3 receptor
glycosylation was upregulated in MV4-11 MID-Res cells versus
MV4-11 MID-Sens cells (Figs. 1b and S5). To determine the
impact of midostaurin on FLT3 receptor activity, MV4-11 and
MOLM-13 MID-Sens and MID-Res cells were treated with 50 nM
midostaurin for 24 h. A single cycle of midostaurin treatment
increased FLT3 receptor glycosylation in MID-Sens and MID-Res
cells. However, the reduction in tyrosine 969 phosphorylation was
more pronounced in MID-Sens than in MID-Res cells (Figs. 1b
and S5), with MID-Res cells showing no reduction in FLT3
phosphorylation. The FLT3 glycosylation level was correlated
with FLT3 surface expression. As expected, FLT3 surface
expression as measured by flow cytometry was increased in MV4-
11 and MOLM-13 MID-Res cells compared with the respective
MID-Sens cells (Fig. 1c). Moreover, dSTORM revealed the exis-
tence of FLT3 clusters in the plasma membrane of MID-Res cells,
which was not observed in MID-Sens cells (Fig. 1d).
Next, we quantified RAC1 activation (RAC1-GTP) in our two
model cell lines: RAC1-GTP levels were increased in MV4-11 and
MOLM-13 MID-Res cells compared to their respective MID-Sens
cells (Fig. 1e). A single dose of midostaurin significantly decreased
RAC1 activation in MV4-11 and MOLM-13 MID-Sens cells
(Fig. 1e), but RAC1 activation was not reduced by 50 nM
midostaurin in MID-Res cells (Fig. 1e). To show that FLT3 was
responsible for RAC1 hyperactivation in MV4-11 and MOLM-13
MID-Res cells, we performed siRNA knockdown (KD) of FLT3
(Figs. 1f). FLT3 KD significantly reduced RAC1 activation in
MV4-11 and MOLM-13 MID-Res cells (Fig. 1f). Moreover, FLT3
KD reversed midostaurin resistance in MV4-11 and MOLM-13
MID-Res cells (Fig. S1A).
The RAC1 inhibitor Eht1864 overcomes midostaurin resis-
tance by inducing cell cycle arrest in G1 and apoptosis in MID-
Res cell lines and primary samples. To define the functional role
of RAC1 activation in resistance to midostaurin, we treated cells
with the specific RAC1 inhibitor Eht1864. Eht1864 binds to
RAC1 and keeps it in an inert and inactive RAC1 state, which
prevents GEF-mediated nucleotide exchange as well as RAC1
binding to downstream effectors20. In our experiments, Eht1864
in combination with midostaurin synergistically reduced cell
viability in MV4-11 and MOLM-13 MID-Res cells (Fig. 2a). This
combination induced cell cycle arrest in G1 phase after 24 h of
treatment (Fig. 2b). Subsequently, apoptosis activation and cell
death induction in MID-Res cell lines were observed by caspase-3
cleavage protein and annexin V/PI assays upon treatment with
this combination for 24 and 48 h, respectively (Figs. 2c).
Once we confirmed that RAC1 inhibition overcomes mid-
ostaurin resistance, we explored the effect of this combination in
cells obtained from patients with refractory FLT3-ITD+ and
FLT3-TKD+AML. A 24-h treatment with Eht1864 in combina-
tion with midostaurin synergistically reduced the viability of
relapsed cells by inducing cell death (Fig. 2d, e). In addition, this
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combination did not induce toxicity in peripheral blood mono-
nuclear cells (PBMCs) obtained from healthy donors (Fig. 2e).
Midostaurin-dependent actin polymerization machinery is
overexpressed in midostaurin-resistant cells. To understand the
underlying mechanisms of RAC1-induced midostaurin resis-
tance, we focused on the genes that regulate actin polymerization.
We found that the protein levels of total and phosphorylated N-
WASP, WAVE2, and PFN1 were enhanced in MV4-11 and
MOLM-13 MID-Res cells compared to their respective MID-Sens
cells (Fig. 3a). Additionally, the expression of WASP protein (48%
homology to N-WASP), which possesses lower actin poly-
merization activity than N-WASP, was upregulated in MV4-11
and MOLM-13 MID-Res versus their respective MID-Sens cells
(Figs. 3a and S6). To determine the impact of midostaurin on the
regulation of the actin polymerization machinery, MV4-11 and
MOLM-13 MID-Sens and MID-Res cells were treated for 24 h
with 50 nM midostaurin. A single treatment cycle of midostaurin
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reduced WAVE2 phosphorylation but not N-WASP phosphor-
ylation in MV4-11 and MOLM-13 MID-Res cells (Figs. 3a and
S6). Treatment with FLT3 KD and the RAC1 inhibitor Eht1864
reversed midostaurin resistance, reduced N-WASP phosphor-
ylation in MV4-11 and MOLM-13 MID-Res cells (Figs. 3b). To
determine whether the midostaurin response was regulated via
actin polymerization, WAVE2, N-WASP, WASP, the ARP2/3
complex, and PFN1 were specifically targeted by siRNAs. The
inhibition of N-WASP, the ARP2/3 complex, PFN1 and WASP
reduced the proliferation of MV4-11 and MOLM-13 MID-Res
cells over four days (Figs. 3c and S2A). However, WAVE2 KD did
not induce any change in the proliferation of MV4-11 and
MOLM-13 MID-Res cells (Fig. 3c). The IC50 of midostaurin was
significantly reduced in MV4-11 and MOLM-13 MID-Res cells
with N-WASP/ARP2/PFN1 KD compared to cells treated with
scramble (Fig. 3c). No changes in the IC50 value of midostaurin
were observed in MV4-11 and MOLM-13 MID-Res cells with
WAVE2 and WASP KD (Figs. 3c, d and S2A). The decrease in
cell viability observed upon N-WASP/ARP2/3/PFN1 inhibition
was due to cell death induction, and this decrease was enhanced
by midostaurin treatment (Fig. S2B). Additionally, the actin
cytoskeleton disruptor Cytochalasin D and ARP2/3 small-
molecule inhibitor CM-636 reversed midostaurin resistance in
MID-Res cells via cell death induction (Fig. S2C).
To determine whether this regulation occurs in AML patients,
correlation analysis between the expression of actin polymeriza-
tion positive regulators (N-WASP, WAVE2, ARP2/3 complex,
PFN1) and FLT3 signaling genes was performed by using publicly
available microarray expression data (E-MTAB-3444). A positive
correlation between the expression of these four inducers of actin
polymerization and FLT3 signaling genes was observed in
patients with FLT3-ITD (r= 0.67, n= 178) and FLT3 WT (r=
0.57, n= 461) de novo AML (Fig. 3e). Correlating the expression
of each activator of actin polymerization individually with FLT3
pathway gene expression showed a moderate positive correlation
for WAVE2/PFN1/ARP2 in FLT3-ITD and FLT3 WT de novo
AML patients (Fig. S3A–C), but no correlation was observed
between N-WASP and FLT3 pathway gene expression (Fig. S3D).
RAC1 hyperactivation increases cell stiffness and enhances
adhesion forces to mesenchymal stromal cells in midostaurin-
resistant FLT3-ITD+ AML cells. ARP2/3 activation is essential
in the induction of actin polymerization21. The grade of actin
polymerization positively correlates with actin filament growth,
which is an important regulator of cell mechanical properties
such as cell stiffness22–24. To show that the ARP2/3 complex was
overactivated in MV4-11 and MOLM-13 MID-Res cells, we
analyzed the actin filament load and stiffness in MV4-11 and
MOLM-13 MID-Sens and MID-Res cells. We first visualized the
load of actin filaments by high-resolution structured illumination
microscopy (SIM) and observed an increased number of actin
filaments in MV4-11/MOLM-13 MID-Res cells compared to their
respective MID-Sens cells (Fig. 4a). Then, MV4-11 and MOLM-
13 MID-Res cells were treated with the combination of Eht1864
and midostaurin for 24 h, and we observed a drastic reduction in
the number of actin filaments in MV4-11 and MOLM-13 MID-
Res cells (Fig. 4a). To assess changes in cell stiffness, we applied
FluidFM®, a new microfluidic technology adapted to traditional
atomic force microscopy (AFM)25, which confirmed significant
increases in cell stiffness in MV4-11 and MOLM-13 MID-Res
cells compared to MID-Sens cells (Fig. 4b). Likewise, the com-
bination of Eht1864 and midostaurin for 24 h reduced cell stiff-
ness in MV4-11 and MOLM-13 MID-Res cells (Fig. 4b).
Moreover, as previously described by others, RAC1 activation
increases the adhesion forces of cancer cells to mesenchymal
stromal cells (MSCs), which negatively impacts the therapeutic
response26. Accordingly, we independently co-cultured MID-Sens
and MID-Res cells with the MSC line HS-5 for 24 h. The adhesion
forces of MV4-11 MID-Res cells to HS-5 cells as well as those of
MID-Sens cells to HS-5 cells were assessed by FluidFM®, and
MV4-11 MID-Res cells were attached more strongly to HS-5 cells
than were the MID-Sens cells (Fig. 4c and Supplementary
Movies 1–2). Strikingly, the combination of Eht1864 and mid-
ostaurin (incubated for 24 h) was able to detach MV4-11 MID-
Res cells from the MSCs (Supplementary Movies 3–5).
The combination of Eht1864 and venetoclax reverses mid-
ostaurin resistance by blocking the antiapoptotic axis BCL-2/
MCL1. As RAC1 is a positive regulator of BCL-2/MCL1, we
studied the role of the BCL-2 family in the response to mid-
ostaurin in FLT3-mutant AML. BCL-2 and MCL1 expression was
strongly upregulated in MV4-11 MID-Res cells compared to their
parental cells (Figs. 5a); no changes were observed in MOLM-13
cells. To determine the role of midostaurin in BCL-2/MCL1
regulation, MV4-11 and MOLM-13 MID-Sens and MID-Res cells
were treated with 50 nM midostaurin for 24 h. MCL1 expression
was decreased by midostaurin in MV4-11 and MOLM-13 MID-
Sens and MID-Res cells (Figs. 5a); however, BCL-2 expression
was increased by midostaurin in MID-Sens cells (Figs. 5a). In
addition, MV4-11 and MOLM-13 MID-Res cells were more
sensitive to the BCL-2 inhibitor venetoclax than were the
respective MID-Sens cell lines (Fig. 5b). Notably, the combination
of midostaurin and Eht1864 decreased MCL1 expression but not
BCL-2 expression in MV4-11 and MOLM-13 MID-Res cells
(Figs. 5c). BCL-2 in the absence of MCL1 sequesters the proa-
poptotic proteins BIM/BAX/BAK and partially inhibits
apoptosis27. Thus, BCL-2 expression could induce secondary
resistance to the combination of midostaurin and Eht1864 in
AML. Thus, we hypothesized that venetoclax would exhibit
synergistic effects of with the midostaurin/Eht1864 combination
therapy. Notably, venetoclax in combination with either mid-
ostaurin or Eht1864 synergistically reduced the viability of MV4-
11 and MOLM-13 MID-Res cells by significantly abrogating
MCL1/BCL-2 expression and inducing cell death (Figs. 5d, e and
Fig. 1 FLT3 dependent RAC1 hyperactivation in MV4-11/MOLM-13 Midostaurin-resistant cells. a Midostaurin (Mid) IC50/cell viability and FLT3
glycosylation/phosphorylation analysis in MV4-11/MOLM-13 Mid sensitive (MID-Sens) and resistant (MID-Res) cells. b FLT3 phosphorylation/
glycosylation was analyzed in MV4-11/MOLM-13 MID-Sens ±MID and MID Res ±MID by Western blot. FLT3 blot, G means glycosylated band (160 kDa)
and NG, non glycosylated band (130 kDa). c FLT3 surface expression was analyzed in MV4-11/MOLM-13 MID-Sens ±MID and MID Res ±MID by flow
cytometry. d FLT3 receptor was analyzed in MV4-11 MID-Res versus MID-Sens by super-resolution microscopy dSTORM. e RAC1 activation was analyzed
in MV4-11/MOLM-13 MID-Res ±Mid 50 nM compared to MID-Sens cells ±Mid 50 nM (MID-Sens+Mid 50 nM versus MID-Sens−Mid (MV) p=
0.059, t= 3.4, df= 2.3 (MO) p= 0.07, t= 3.1, df= 2.3; MID-Res−Mid versus MID-Sens−Mid (MV) p < 0.01, t= 6.1, df= 3.8 (MO) p < 0.01, t= 5.7, df
= 3.9; MID-Res+Mid versus MID-Sens (MV) p < 0.01, t= 10.03, df= 2.7 (MO) p < 0.01, t= 6.5, df= 3.4). f RAC1 activation was analyzed in FLT3 KD
MV4-11/MOLM-13 MID-Res compared to scramble MV4-11 MID-Res cells ((MV) p < 0.01, t= 8.56, df= 2.9, (MO) p < 0.01, t= 5.1, df= 3.5). Relative
light units (RLU). The western blot results are normalized by loading control (GAPDH) and are expressed as fold change relative to the control. Data are
shown as means ± SDs (error bars) from three independent experiments.
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S4A, B). The results were confirmed in primary samples from two
patients with refractory FLT3-ITD AML; cell death was induced
in the majority of cells (>65%) (Fig. 5f). Of note, this triple
combination was not toxic in PBMCs obtained from three healthy
donors (Fig. 5f).
Discussion
Activation of the PI3K and JAK/STAT pathways is a known
resistance mechanism against FLT3 inhibition in FLT3-ITD
AML28–31. RAC1 is a positive regulator of both pathways and
interacts with FLT310,32. This cross talk mediates drug resistance
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against classical chemotherapy via regulation of DNA repair
pathways10,19. However, the role of RAC1 in the efficacy of FLT3
inhibitors in the treatment of FLT3-ITD leukemia has not yet
been determined. Our study provides the first evidence that
RAC1-dependent actin cytoskeleton remodeling and inhibition of
apoptosis may underlie midostaurin resistance in FLT3-ITD AML.
FLT3-ITD mutations, which increase FLT3 autopho-
sphorylation, lead to the activation of RAC1 in AML10,33. Clinical
responses to FLT3 inhibitors have been correlated with the
inhibition of FLT3 phosphorylation7. Moreover, FLT3 receptor
glycosylation that is induced by FLT3 inhibitors, has been asso-
ciated with FLT3 inhibitor resistance9. Accordingly, we observed
increases in FLT3 phosphorylation/glycosylation and RAC1
hyperactivation in MV4-11 and MOLM-13 cells resistant to
midostaurin, which was reversed by specifically targeting the
FLT3 receptor. We used Eht1864, a specific RAC1 inhibitor, to
investigate the effects of its hyperactivated state on midostaurin
resistance. This compound is 20-fold more potent than other
RAC1 inhibitors (Nsc23766) used in other AML studies10.
Eht1864 reversed midostaurin resistance by inducing cell cycle
arrest in G1 and activating apoptosis in established FLT3-ITD
AML cell lines and in primary cells obtained from refractory
AML patients with FLT3-ITD and FLT3-TKD D835 mutations.
Weisberg et al. demonstrated that midostaurin reduces the via-
bility of FLT3-mutated Ba/F3 leukemia cell lines and mouse
models by inducing G1 arrest and apoptosis6. Therefore, this
study corroborates our result that RAC1 inhibition overcomes the
antitumor activity of midostaurin in FLT3-mutant clones resis-
tant to midostaurin. Of note, Eht1864 and midostaurin either
alone or in combination did not show any toxicity in PBMCs
obtained from healthy donors. These results are in accordance
with other studies, where no cell death was observed in healthy
cells treated with these compounds 17,34.
RAC1 is a master regulator of actin cytoskeleton rearrangement35.
RAC1 is activated by binding to N-WASP and WAVE2, which
induces the conformational activation of these two proteins. Then, N-
WASP and WAVE2 can bind to the ARP2/3 complex and activate it,
resulting in actin polymerization36,37. The phosphorylation of N-
WASP and WAVE2 is positively correlated with binding to the
ARP2/3 complex and actin polymerization activation36,37. Any dys-
regulation in actin polymerization regulators favors cancer cell pro-
liferation, migration, metastases and drug resistance in solid
tumor15,38. However, their role in treating hematological malig-
nancies has not yet been described. Here, we provide evidence that in
FLT3-ITD AML, RAC1-dependent actin cytoskeleton remodeling
plays a substantial role in the acquisition of resistance to midostaurin
in vitro. N-WASP and WAVE2 phosphorylation is upregulated in
midostaurin-resistant cells. N-WASP-specific KD but not WAVE2
KD reversed midostaurin resistance. Moreover, ARP2/3 complex
inhibition by the small-molecule inhibitor CK-636 and siRNAs
restored midostaurin activity. These results show the importance of
N-WASP phosphorylation and ARP2/3 complex activation in mid-
ostaurin resistance in FLT3-mutant AML. Regarding WAVE2,
because midostaurin is able to reduce its phosphorylation, we think
that WAVE2 is not critical for midostaurin resistance in AML. In
addition, proteins that stimulate actin polymerization, such as PFN1,
have been associated with resistance to the proteasome inhibitor
bortezomib in multiple myeloma.39. Additionally, we demonstrated
that PFN1 expression is correlated with midostaurin resistance in
FLT3-mutant AML cells.
Overactivation of actin polymerization leads to increased
production of actin filaments40. As expected, MV4-11 and
MOLM-13 midostaurin-resistant cells showed an increase in the
number of actin filaments and cell stiffness compared to their
respective midostaurin-sensitive parental cells. In line with our
results, recent studies have described that tumor stiffening pro-
motes resistance to the tyrosine kinase inhibitor sorafenib in
triple-negative breast cancer cells and that cell rigidity is higher in
cisplatin-/paclitaxel-resistant ovarian cancer cells versus parental
ovarian cancer cells41–43. Moreover, massive actin filament
accumulation has been associated with resistance to natural killer
cell-based immunotherapy and chemotherapy in ovarian and
breast cancers, respectively43,44. These results suggest that the
cytoskeletal architecture and physical properties of cancer cells
could play a critical role in drug resistance and could be novel
parameters to evaluate therapy response.
It has been hypothesized that remodeling of the actin cytos-
keleton is a strategy by which tumor cells evade apoptosis45. In
fact, RAC1 blocks apoptosis by stabilizing the antiapoptotic
proteins BCL-2 and MCL1 and upregulating their expression in
cancer17,18. In line with that, MV4-11 MID-Res cells showed
higher BCL-2 and MCL1 expression than did the parental cells. A
single dose of midostaurin decreased MCL1 expression in sensi-
tive and resistant cell lines. However, BCL-2 expression was
upregulated under midostaurin treatment. As RAC1 activation is
reduced under Midotaurin treatment in MV4-11 and MOLM-13
parental cell lines, RAC1 might regulate MCL-1 stability but not
BCL2. Further investigation is needed to elucidate the role of
RAC1 in the stability of BCL2/MCL-1 in MID-Sens/MID-Res
cells. Due to BCL2 overexpression, higher sensitivity to the BCL-2
inhibitor venetoclax was observed in resistant cells than in sen-
sitive cells. Recently, Ma et al. described that FLT3 inhibitors such
as midostaurin and gilteritinib sensitize FLT3-ITD de novo AML
cells to venetoclax by reducing MCL1 expression34. To induce full
apoptosis in cancer cells, inhibition of MCL1 and BCL-2 is
needed46. The combination of midostaurin and Eht1864 degrades
MCL1 but increases BCL-2 expression. BCL-2 sequesters proa-
poptotic genes such as BIM and partially inhibits apoptosis47.
Therefore, we believe that BCL-2 expression may contribute to
secondary resistance to Eht1864 and midostaurin combination
therapy. Consequently, we decided to add venetoclax, which was
recently approved by the FDA in combination with hypo-
methylating agents or low-dose cytarabine for elderly individuals
(75 years or older) with newly diagnosed AML or those who have
comorbidities precluding intensive induction chemotherapy, to
investigate whether BCL-2 inhibition enhanced the antitumor
activity of the Eht1864/midostaurin combination therapy in
FLT3-mutant AML. Strikingly, this triple combination compris-
ing Eht1864, venetoclax and midostaurin synergistically reduced
the viability of FLT3-ITD midostaurin-resistant cells and cells
Fig. 2 RAC1 inhibitor Eht1864 overcomes Midostaurin resistance by the induction of cell cycle arrest in G1 and apoptosis in MID-Res cell lines as well
as primary samples. a The cell viability and synergy analysis of Mid+ Eht1864 (Eht) combination was done in MV4-11/MOLM-13 MID-Res treated with
these compounds during 48 h. b The cell cycle analysis was carried out in MV4-11 MID-Res treated with Mid and Eht alone/combination during 24 h. c The
apoptosis was studied by caspase-3 cleavage monoclonal antibody and cell death % was defined by Annexin V+ /PI−+Annexin V+ PI+ in MV4-11/
MOLM-13 MID-Res cells treated with Mid and Eht alone/combination during 24 and 48 h, respectively. d Cell viability and synergy analysis of Eht+Mid
combination was done in Refractory (REF) REF001/REF002 samples treated with these compounds during 48 h. e The apoptosis analysis in REF001/
REF002 and in PBMCs obtained from healthy donors treated with Mid and Eht alone/combination during 24 h. Data are shown as means ± SDs (error
bars) from three independent experiments.
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obtained from patients with FLT3-ITD refractory AML by
reducing MCL1 and BCL-2 expression. Notably, no apoptosis was
observed in PBMCs obtained from healthy donors treated with
the triple combination therapy.
In summary, we propose a new midostaurin resistance
mechanism in FLT3-mutated AML cells, in which actin cytos-
keleton remodeling by FLT3-dependent RAC1 activation, N-
WASP phosphorylation and ARP2/3 complex activation favors
AML cell survival and proliferation. Moreover, RAC1 hyper-
activation inhibits apoptosis by affecting MCL1/BCL2 expression,
changes the mechanical properties of these cells and increases the
adhesion forces of FLT3-ITD AML cells to MSCs (Fig. 6a). Based
on these findings, under the condition that this combination is
safe and feasible, we see clinical potential in combining mid-
ostaurin, venetoclax and Eht1864 as a novel therapeutic strategy
to treat FLT3-mutant AML patients (Fig. 6b).
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Material and methods
Human samples and cell lines. The human AML cell line MV4-
11 (homozygous FLT3-ITD) and MOLM-13 (heterozygous FLT3-
ITD) were used for in vitro studies. Midostaurin-resistant cell
lines were developed as follows: (1) 1 × 106/ml MV4-11 and
MOLM-13 cells were plated in 24-well plates in 2 ml cell culture
medium and treated with 10 nM Midostaurin, (2) every 7 days,
leukemia cells were adjusted to 1 × 106/ml in fresh medium and 2
ml of this cell suspension plated per well in 24-well plates, and (3)
MV4-11 and MOLM-13 cells were initially exposed to 10 nM
Midostaurin and concentration was increased serially (increased
by 10 nM weekly) up to 50 nM. MV4-11 and MOLM-13 parental
cell lines were purchased from ATCC and DSMZ, respectively.
They were maintained in culture in RPMI-1640 medium sup-
plemented with 10% fetal bovine serum with 1% penicillin-
streptomicin and 1% L-Glutamine at 37 °C in a humid atmo-
sphere containing 5% CO2 at a concentration of 2 × 105 to 1 ×
106. HS-5 MSC line was kindly provided by Patricia Maiso
laboratory and were maintained in DMEM medium supple-
mented with 10% fetal bovine serum with 1% penicillin-
streptomicin 1% L-Glutamine at 37 °C in a humid atmosphere
containing 5% CO2 at a concentration of 5 × 105 to 1 × 106. The
cell lines were tested for mycoplasma contamination monthly.
BM mononuclear cells were obtained from refractory FLT3-
mutated AML patients after an informed consent was signed by
the patients or the patient’s guardians, in accordance with the
Declaration of Helsinki. Clinical characteristics of relapsed FLT3-
mutated AML patients used in this study are explained in
Table S1. To test the toxicity of the compounds that were used in
this work, we used PBMCs obtained from three healthy donors.
dSTORM analysis of FLT3 receptor expression. Localization
data were analyzed by custom-made code written in Mathematica
11.1 (Wolfram Research Inc.). From each dSTORM image an
appropriate region of interest was identified and localizations
within this region of interest were selected. A DBSCAN clustering
algorithm (Elki Data Mining) was applied to group localizations
according to their local density48. Parameters were chosen by
scanning the parameter space for weakest dependency of the
resulting clustering set (neighborhood radius or epsilon= 20;
minPoints= 3).
Dye conjugation to antibodies. After buffer exchange using 0.5 ml
7 kDa Spin Desalting Columns (Thermo Fisher, 89882, Erlangen,
Germany) in 100 mM NaHCO3 50 µg of the purified monoclonal
anti-FLT3 (BD Biosciences 558995, Heidelberg, Germany) were
incubated in a five molar excess with Alexa Fluor 647 NHS
(Thermo Fisher Scientific, A20101MP, Erlangen, Germany) at RT
for 3 h in the dark. To exchange the buffer to 0.02 NaN3 and to
remove unreacted dyes the antibodies were purified with 0.5 ml 7
kDa Spin Desalting Columns. Lastly, the degree of labeling of the
conjugated antibody was measured by a UV–vis
spectrophotometer (Jasco V-650). The conjugated antibodies
were stored at 4 °C.
Live cell immunostaining. For super-resolved imaging 1.5 × 105
MV4-11 cells per well were seeded in poly-D-lysine coated
chambers (Lab-Tek II, Nunc, Thermo Fisher Scientific, Erlangen,
Germany) and the cells adhered at 37 °C at 5% CO2 for 1 h. For
live cell staining the cells were incubated for 30 min on ice in an
antibody concentration of 2.5 µg/ml in PBS. Following by wash-
ing of the cells and fixation for 15 min in 2% formaldehyde and
0.2% glutaraldehyde. After three more washing steps the cells
were stored at 4 °C until in PBS imaging.
dSTORM imaging. The dSTORM samples were imaged on a
homebuilt widefield setup with an inverted microscope (Olympus
IX-71) using an oil immersion objective (Olympus APON 60xO
TIRF, NA 1.49). The dyes were excited with a laser of the
wavelength 639 nm (Genesis MX639-1000, Coherent) The exci-
tation light was filtered from the fluorescence light by a beam
splitter (ZT405/514/635rpc, Chroma) and an emission filter
(Brightline HC 679/41, Semrock). Imaging was carried out with
an EMCCD camera (iXon Ultra 897, Andor) for 15,000 frames at
a rate 50 Hz at ~7 kW/cm in 100 mM ß-mercaptoethylamin pH
7.4. The super-resolved dSTORM images were reconstructed with
the open source software rapidSTORM 3.349.
RAC1 activation assay. RAC1 activation was measured by RAC1
G-LISATM kit (Cytoskeleton BK126, Denver, CO, USA). This kit
provides RAC1-GTP-binding protein linked to the wells of a 96
wells plate. The bound active RAC1 is detected with a
RAC1 specific antibody and luminescence. The RAC1 activation
was analyzed in MV4-11/MOLM-13 MID-Res ±50 nM Mid-
ostaurin compared to their parental cells ±50 Nm Midostaurin
and FLT3 KD MV4-11/MOLM-13 MID-Res versus scramble
MV4-11/MOLM-13 MID-Res. Following the kit instructions,
these cells were incubated in serum free medium during 24 h to
inactivate RAC1 In the case of FLT3 KD and scramble MV4-11/
MOLM-13 MID-Res cells serum starvation was done 48 h after
siRNAs transfection, to be sure that FLT3 was knocked down.
Then, 5.106 MID-Sens/MID-Res cells ±50 nM Midostaurin dur-
ing 30 min (At this time were observed the highest differences). In
FLT3 KD experiment, 5.106 FLT3 KD/scramble MID-Res cells
after serum starvation, were placed in supplemented RPMI-1640
medium at 37 °C in a humid atmosphere during 30 min. Then,
the cells were harvested, lysates and protein was quantified by
Precision RedTM Advanced Protein Assay Reagent (Cytoskeleon
GL50). The final concentration used of equalized lysates was 1
mg/ml. Anti-RAC1 primary and the secondary HRP labeled
antibody were diluted 1:5000. This antibody dilution allowed that
readings were in the linear range of the luminometer. RAC1
activation Relative Light Units (RLU) was calculated by resting
the lysis Buffer RLU mean (used as reference blank) to MID-
Fig. 3 FLT3 dependent RAC1 activation promotes dysregulation of actin polymerization regulators in Midostaurin-resistant cells. a The protein
expression analysis of actin polymerization positive (red) and negative (green) regulators by western blot in MV4-1/MOLM-13 MID-Res compared to
parental cells, in MV4-11/MOLM-13 MID-Res ± 50 nM Mid compared to MID-Sens ± 50 nM Mid. b In FLT3 KD MV4-11/MOLM-13 MID-Res compared to
scramble MV4-11 MID-Res and in MV4-11 MID-Res treated with Mid and Eht alone/combination. GAPDH was used as housekeeping. c Proliferation and
Mid IC50 (after 4 days) in MV4-11/MOLM-13 MID-Res N-WASP KD ((MV) p < 0.0001, t= 25.7, df= 3.8, (MO) (p < 0.001, t= 10.5, df= 3.9)), WAVE2
KD ((MV) p= 0.32, t= 1.1, df= 2.93, (MO) p= 0.4, t= 1, df= 2.6), ARP2/3 complex KD ((MV) p < 0.001, t= 39.6, df= 2.06, (MO) p < 0.001, t= 11.8,
df= 3.6), and PFN1 KD ((MV) p < 0.001, t= 25.1, df= 3.9, (MO) p < 0.001, t= 9.8, df= 3.5) compared to scramble MID-Res cells. d Actin polymerization
positive regulators protein expression analysis targeting them by siRNAs in MV4-11/MOLM-13 MID-Res. e Correlation analysis between the mean of actin
polymerization positive regulators (N-WASP, WAVE2, ARP2, PFN1) and FLT3 pathway genes expression in 639 AML patients by using microarray
expression data (E-MTAB-3444). The western blot results are normalized by loading control (GAPDH) and are expressed as fold change relative to the
control. Data are shown as means ± SDs (error bars) from three independent experiments.
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Fig. 4 Deregulation of cell mechanical properties and enhancement of cell adhesion to mesenchymal stromal HS-5 cells in MV4-11/MOLM-13
Midostaurin-resistant cells compared to sensitive cells. a Actin filaments visualization in MV4-11/MOLM-13 MID-Res versus MID-Sens cells and MV4-
11/MOLM-13 MID-Res treated with the combination 50 nM Mid+ 7.5 µM Eht versus MID-Res treated with 50 nM Mid+DMSO during 24 h. b Cell
stiffness analysis in MV4-11/MOLM-13 MID-Res compared to MID-Sens cells ((MV) p < 0.001, F= 14.8, df= 1, (MO) p < 0.05, F= 6.4, df= 1) and in
MV4-11/MOLM-13 MID-Res treated with the combination 50 nM Mid+ 7.5 µM Eht versus MID-Res treated with 50 nM Mid+DMSO (vehicle control)
during 24 h ((MV) p < 0.05, F= 5.3, df= 1, (MO) p < 0.01, F= 9.3, df= 1)*. c Cell adhesion forces quantification in MV4-11 MID-Sens/HS-5 cells and
MV4-11 MID-Res/HS-5 (p < 0.05, F= 4.3, df= 1)*. Data are shown as means ± SDs (error bars) from three independent experiments. *Due to technical
limitations, EHT1864 monotherapy was not performed in stiffness/cell adhesion assays.
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Sens/MID-Res ±Midostaurin RLU mean MID-Res scramble/
MID-Res FLT3 KD RLU mean.
Cell death and cell cycle analysis. The cell death and cell cycle
assay were carried out as described previously 50.
Cell viability assay and cell treatments. Cell viability was analyzed
by CellTiter-Glo® Luminescent Cell Viability Assay (Promega,
Madison, WI, USA) following manufacturer’s instruction. All
experiments were repeated three times. ABT-199 (Venetoclax), EHT
1864 2HCl (Eht1864), PKC412 (Midostaurin) and CK-636 com-
pounds were purchased from selleckhem (Munich, Germany).
Cytochalasin D was purchased from Sigma-Aldrich (Munich, Ger-
many). To understand the mechanism by which the combination of
Midostaurin+Eht1864, Midostaurin+Venetoclax, and Eht1864+
Midostaurin+Venetoclax overcome Midostaurin resistance, MV4-11
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02215-w
10 COMMUNICATIONS BIOLOGY |           (2021) 4:799 | https://doi.org/10.1038/s42003-021-02215-w | www.nature.com/commsbio
and MOLM-13 MID-Res cells were treated at the half maximal
inhibitory concentration (IC50) and maintained in culture for one
day. Then, the cells were washed in PBS and used for different assays.
The IC50 value was determined using GraphPad Prism software, log
(inhibitor) versus response variable slope from dose-response inhibi-
tion (version 5, La Jolla, CA, USA). The synergistic between these
compounds in Midostaurin-resistant cells was evaluated by Compu-
syn software.
Correlation analysis between the expression of actin poly-
merization inducers and FLT3 signaling in AML patients. Meta
information and gene expression data of 639 AML patients were
obtained from ArrayExpress (E-MTAB3444)51. Raw data were RMA
normalized using the {affy} package and multiple probes per gene
were aggregated by mean. FLT3 target gene expression was correlated
with the expression of N-WASP, WASF2, PFN1, ARP2 or the mean
expression of these four genes (“inducers of actin polymerization”)
dependent on the FLT3 mutation status of the patient. FLT3 target
genes (n= 61) were extracted from PathCards (https://pathcards.
genecards.org/; using the “FLT3 signaling” SuperPath52.
Cell stiffness assay. The stiffness of MID-Sens and MID-Res cells
was assessed by using FluidFM® (Cytosurge AG, Glattbrugg
(Zurich), Switzerland), a new technology adapted to traditional
AFM in a Flex-FPM system (Nanosurf GmbH, Langen, Ger-
many). It is mounted on an Axio Observer Z1 inverted micro-
scope (Carl Zeiss, Germany) and a piezoelectric stage of 100 µm
retraction range. Micropipette cantilevers (Cytosurge AG, Swit-
zerland) of 8 µm aperture diameter and 0.33 N/m nominal spring
constant were used. For the measurements of the stiffness of cells,
a cell was immobilized at the aperture of the cantilever by
applying a soft underpressure of 30 mbar, then, approaching at
500 nm/s, it was softly pressed against the culture dish until a set
point of 3 nN was reached, while acquiring the data points at
3500 Hz. Then the cantilever was retracted, cleaned with NaClO
5% and thoroughly rinsed 4 times with ultrapure water and PBS.
The procedure was repeated with 20 cells. The data points cor-
responding to the approach curves were extracted and processed
in MATLAB 2017b (Mathworks, Natick, MA, USA) and fitted
with the Hertz Model to obtain the modulus of elasticity, as
indicator of the cell stiffness, as explained before53. The cell
stiffness was measured in Midostaurin-resistant compared to
Fig. 5 The cell viability and MCL1/BCL-2 protein expression analysis in MV4-11/MOLM-13 Midostaurin-resistant cells treated with the triple
combination Eht1864/Venetoclax/Midostaurin. a BCL-2 and MCL1 protein expression analysis in MV4-11/MOLM-13 MID-Res compared to MID-Sens
cells, in MV4-11/MOLM-13 MID-Res ± 50 nM Mid compared to MID-Sens ± 50 nM Mid. b Venetoclax (Ve) IC50 analysis in MV4-11/MOLM-13 MID-Sens
and MID-Res cells treated with Ve during 48 h. c BCL-2 and MCL1 protein expression analysis in MV4-11/MOLM-13 MID-Res treated with Mid and Eht
alone/combination. d Cell viability and synergy analysis in MV4-11/MOLM-13 MID-Res treated with Mid, Ve, and Eht alone/combination during 48 h. e
BCL-2 and MCL1 protein expression and cell death analysis (Annexin V+ /PI-+Annexin V+ PI+) in DMSO (control), Mid (p= 0.76, t= 0.34, df= 2.3),
Ve (p= 0.054, t= 2.7, df= 3.6), Eht (p < 0.05, 3.1, df= 3.7) and Mid+ Eht (p < 0.01, t= 10.29, df= 3) Mid+Ve (p < 0.01, t= 8, df= 3.8) Ve+ Eht (p <
0.001, t= 14, df= 3.9) and Eht+Ven+Mid (p < 0.001, t= 16.1, df= 3.2) during 24 h. f Cell death analysis by flow cytometry in REF001/REF002 AML
samples and in PBMCs obtained from Healthy Donors HD4/HD5/HD6 treated with Mid, Eht, and Ve alone/combination during 24 h. The western blot
results are normalized by loading control (GAPDH) and are expressed as fold change relative to the control. Data are shown as means ± SDs (error bars)
from three independent experiments.
Fig. 6 Summary results figure. a Overactivation of actin polymerization machinery and antiapoptotic BCL-2 family in FLT3-ITD Midostaurin-resistant AML
cells. b The triple combination Eht1864/Venetolax/Midostaurin by targeting Actin polymerization and BCL-2 reversed Midostaurin resistance.
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sensitive cells and resistant cells treated with the combination 7.5
µM Eht1864+ 50 nM Midostaurin versus resistant cells+ 50 nM
Midostaurin during 24 h.
Adhesion forces assay. In total, 1.106 HS-5 cells were cultured in
a 6 well plate for 24 h. Then, 5.105 MID-Sens and MID-Res cells
were independently co-cultured with the stromal layer in serum
free conditions for 24 h. Afterwards, we quantified and compared
the cell adhesion forces of MID-Res and MID-Sens onto HS-5
cells. The quantification of adhesion forces was performed by
using the above-described FluidFM® system. Micropipette canti-
levers of 4 µm aperture diameter and a nominal spring constant
of 0.4 N/m were used. MV4-11 MID-Sens or MID-Res cells were
approached with the cantilever at a speed of 5 µm/s until it
pressed the surface of a cell with a set point of 3 nN. Next, the cell
was immobilized at the cantilever aperture by applying an under
pressure of 300 mbar, and retracted at 5 µm/s until complete
detachment from the stromal layer. The cantilever was cleaned
with NaClO 5% and thoroughly rinsed with water and PBS after
measuring each cell. The data acquired during the retraction of
the cantilever were extracted with SPIP 6.2.0 software (Image
Metrology, Copenhagen, Denmark) and the cell-cell adhesion
force was calculated according to Hook’s Law, as explained
before53.
siRNAs electroporation in AML cell lines. SiRNAs against FLT3
receptor (Reference: HSS103748) and actin polymerization
inducers (ARP2 (Reference: HSS115366), N-WASP (Reference:
HSS113263), WAVE2 (Reference: HSS145484) and PFN1
(Reference: HSS107879) were purchased at Thermo Fischer Sci-
entific (Erlangen, Germany). SiRNAs were dispensed into 1.5 ml
Eppendorf tubes and mixed with the cell suspension by gentle
pipetting. The complete range of electroporation mixes was
prepared and electroporation carried out with a Gene Pulser (Bio-
Rad Laboratories, Munich, Germany) at a capacity setting of 960
µF and with 300 voltage.
Flow cytometric analysis of FLT3 receptor expression. Cell
surface expression of FLT3 (CD135) was analyzed using a PE-
conjugated mouse anti-human FLT3 monoclonal antibody (clone
4G8, BD Biosciences, Heidelberg, Germany). In brief, 1 × 106 cells
in 100 µl FACS Buffer (1X PBS+ 1% FCS+ 5 mM HEPES) were
stained with 20 µl of PE-FLT3 (the optimum concentration was
determined after titrating the antibody) for 30 min at 4 °C. After
washing the cells, a viability dye (1:1000) was used (Cat. No.
L34960, Thermo Fisher Scientific, Erlangen, Germany) for 30 min
at room temperature. Cells were washed and resuspended in 300
µl FACS Buffer and analyzed using the CytoFLEX flow cytometer
(Beckman Coulter). 50000 living cells were recorded. The gating
strategy consisted of debris removal (FSC/SSC), double dis-
crimination (FSC-A/H), dead cell exclusion (APC-) and FLT3+.
Analysis was performed using FlowJo V.10.6 (BD Biosciences).
Immunoblotting. Cells were harvested and lysed using lysis
buffer (Thermo Fischer Scientific), reconstituted, and whole-cell
lysates were subjected to SDS-PAGE and transferred to Nitro-
cellulose Blotting Membrane (GEhealthcare Life science). Anti-
Phospho Tyrosin 969 FLT3 (working dilution 1:1000), Anti-
ARP2 (working dilution 1:1000), anti-N-WASP (working dilution
1:1000), anti-WAVE2 (working dilution 1:1000), anti-PFN1
(working dilution 1:1000), anti–MCL1 (working dilution
1:1000), anti–BCL-2 (working dilution 1:1000), and anti-GAPDH
(working dilution 1:2000) antibodies were purchased from Cell
Signaling Technology; The HRP-conjugated secondary antibody
(working dilution 1:5000) were from Cell Signaling Technology.
Moreover, it was used anti-P-N-WASP [Ser484/Ser485] (working
dilution 1:1000) and anti-P-WAVE2 [Ser343] (working dilution
1:1000) from Merck. The quantification of western blots were
done by ImageJ software: (1) We measure the bands and their
backgrounds along with the loading control bands (GAPDH) and
their backgrounds, (2) Invert the pixel density for all data, the
inverted value is expressed as 255—X, (3) after doing the inver-
sions, it was calculated the net value of our net bands and
GAPDH by substracting the inverted background, and (4) was
measured fold change of net band/GAPDH relative to the control
(scramble in siRNAs experiments and untreated sample in
treatments experiment.
Immunofluorescence of actin filaments. In total, 1.5 × 105 cells
were seeded on poly-D-lysine (Sigma, P6407-5MG, Munich,
Germany) coated Lab-Tek chambers (Lab-Tek II, Nunc, Thermo
Fisher Scientific, Erlangen, Germany) and adhered for 1 h at 37 °
C and 5% CO2. Cells were fixed using a cytoskeleton buffer (CB,
10 mM MES buffer pH 6.1, 150 mM NaCl, 5 mM EGTA, 5 mM
glucose, as previously reported54, with an optimized protocol
designed for cytoskeleton staining. Here, the cells were incubated
for 1 min in CB1 (CB+ 0.25% Triton+ 0.3% glutaraldehyde)
followed by a 10 min incubation in CB2 (CB+ 2% glutar-
aldehyde). Thereafter autofluorescence was quenched by an
incubation of 7 min in 0.1% NaBH4 and unspecific binding was
blocked by a 30 min incubation in 5% BSA (Sigma, A3983-100g)
after three washing steps. The cells were stained overnight at 4 °C
in 0.1 µM Atto643-Phalloidin (ATTO-TEC, AD 643-81) in 5%
BSA and stored at 4 °C. Prior to imaging the cells were washed
again and imaged in PBS using a Zeiss Elyra S.1 SIM. The z-
stackes were rendered and processed with Imaris 8.4.1.
Statistics and reproducibility. All the experiments were repeated
three times (Biological triplicates). Data are expressed as means ±
standard deviation. Statistical significance between two samples
was estimated with Student’s t test (two-tailed). Differences with p
values < 0.05 were considered as significant (∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001, and ****p < 0.0001). Statistical significance in
stiffness and adhesion forces assays was estimated with one way
ANOVA test. Statistical analyses were performed utilizing
GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available within the manuscripts and
its Supplementary files. Source data are provided in Supplementary Data 1. Meta
information and gene expression data of 639 AML patients were obtained from
ArrayExpress (E-MTAB3444) 51.
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